Literature DB >> 18264722

Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.

Josenilson C Oliveira1, Kellen K Souza, Marília M Dias, Marcel C Faria, Eduardo R Ropelle, Marcelo B S Flores, Mirian Ueno, Lício A Velloso, Sara T Saad, Mario J A Saad, José B C Carvalheira.   

Abstract

Proper activation of phosphoinositide 3-kinase-Akt pathway is critical for the prevention of tumorigenesis. Recent data have characterized a negative feedback loop, wherein mammalian target of rapamycin (mTOR) blocks additional activation of the Akt/mTOR pathway through inhibition insulin receptor substrate 1 (IRS-1) function. However, the potential of IRS-1 inhibition during rapamycin treatment has not been examined. Herein, we show that IRS-1 antisense oligonucleotide and rapamycin synergistically antagonize the activation of mTOR in vivo and induced tumor suppression, through inhibition of proliferation and induction of apoptosis, in prostate cancer cell xenografts. These data demonstrate that the addition of agents that blocks IRS-1 potentiate the effect of mTOR inhibition in the growth of prostate cancer cell xenografts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264722     DOI: 10.1007/s00432-008-0359-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 2.  The IRS-signalling system during insulin and cytokine action.

Authors:  L Yenush; M F White
Journal:  Bioessays       Date:  1997-06       Impact factor: 4.345

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases.

Authors:  T Ito; Y Sasaki; J R Wands
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

5.  Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

Authors:  H B Jefferies; S Fumagalli; P B Dennis; C Reinhard; R B Pearson; G Thomas
Journal:  EMBO J       Date:  1997-06-16       Impact factor: 11.598

6.  Mammalian TOR: a homeostatic ATP sensor.

Authors:  P B Dennis; A Jaeschke; M Saitoh; B Fowler; S C Kozma; G Thomas
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

Review 7.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

Authors:  Shile Huang; Peter J Houghton
Journal:  Curr Opin Investig Drugs       Date:  2002-02

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 9.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

Review 10.  PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?

Authors:  M A Lawlor; D R Alessi
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

View more
  9 in total

Review 1.  The Role of Autophagy in Salivary Gland Homeostasis and Stress Responses.

Authors:  M Morgan-Bathke; H H Lin; D K Ann; K H Limesand
Journal:  J Dent Res       Date:  2015-06-19       Impact factor: 6.116

Review 2.  Targeting mTOR in cancer: renal cell is just a beginning.

Authors:  Hamdy Azim; Hatem A Azim; Bernard Escudier
Journal:  Target Oncol       Date:  2010-06-20       Impact factor: 4.493

Review 3.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.

Authors:  Jorge A Garcia; David Danielpour
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

Review 4.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

5.  Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

Authors:  Amy J VanMeter; Adrianna S Rodriguez; Elise D Bowman; Jin Jen; Curtis C Harris; Jianghong Deng; Valerie S Calvert; Alessandra Silvestri; Claudia Fredolini; Vikas Chandhoke; Emanuel F Petricoin; Lance A Liotta; Virginia Espina
Journal:  Mol Cell Proteomics       Date:  2008-08-06       Impact factor: 5.911

Review 6.  Impact of targeting insulin-like growth factor signaling in head and neck cancers.

Authors:  Kirsten H Limesand; Alejandro Martinez Chibly; Andrew Fribley
Journal:  Growth Horm IGF Res       Date:  2013-06-29       Impact factor: 2.372

7.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

Authors:  Arkaitz Carracedo; Li Ma; Julie Teruya-Feldstein; Federico Rojo; Leonardo Salmena; Andrea Alimonti; Ainara Egia; Atsuo T Sasaki; George Thomas; Sara C Kozma; Antonella Papa; Caterina Nardella; Lewis C Cantley; Jose Baselga; Pier Paolo Pandolfi
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 8.  The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins.

Authors:  Fumihiko Hakuno; Toshiaki Fukushima; Yosuke Yoneyama; Hiroyasu Kamei; Atsufumi Ozoe; Hidehito Yoshihara; Daisuke Yamanaka; Takashi Shibano; Meri Sone-Yonezawa; Bu-Chin Yu; Kazuhiro Chida; Shin-Ichiro Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-26       Impact factor: 5.555

Review 9.  The Biased G-Protein-Coupled Receptor Agonism Bridges the Gap between the Insulin Receptor and the Metabolic Syndrome.

Authors:  Iryna Liauchonak; Fady Dawoud; Yatin Riat; Bessi Qorri; Manpreet Sambi; Justin Jain; Regina-Veronicka Kalaydina; Nicole Mendonza; Komal Bajwa; Myron R Szewczuk
Journal:  Int J Mol Sci       Date:  2018-02-17       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.